ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ: SPRY · IEX Real-Time Price · USD
10.22
+0.26 (2.61%)
At close: Mar 28, 2024, 4:00 PM
10.49
+0.27 (2.64%)
After-hours: Mar 28, 2024, 7:35 PM EDT
2.61%
Market Cap 1.07B
Revenue (ttm) 30,000
Net Income (ttm) -54.37M
Shares Out 96.50M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,644,589
Open 10.52
Previous Close 9.96
Day's Range 10.16 - 11.27
52-Week Range 2.55 - 11.27
Beta n/a
Analysts Buy
Price Target 18.50 (+81.02%)
Earnings Date Mar 21, 2024

About SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 24
Stock Exchange NASDAQ
Ticker Symbol SPRY
Full Company Profile

Financial Performance

In 2023, SPRY's revenue was $30,000, a decrease of -97.72% compared to the previous year's $1.32 million. Losses were -$54.37 million, 56.8% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for SPRY stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 81.02% from the latest price.

Price Target
$18.5
(81.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SPRY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ARS Pharmaceuticals, Inc.

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

3 days ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceutic...

3 days ago - Accesswire

ATTENTION ARS Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

3 days ago - Accesswire

Investors who lost money on ARS Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - SPRY

NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

7 days ago - Accesswire

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Preparing to submit response to the FDA's CRL for neffy ® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen c...

7 days ago - GlobeNewsWire

ARS Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SPRY

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

7 days ago - Accesswire

ATTENTION ARS Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

9 days ago - Accesswire

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceutic...

9 days ago - Accesswire

An Investigation Has Commenced on Behalf of ARS Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SPRY Losses.

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

9 days ago - Accesswire

Did ARS Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SPRY

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

14 days ago - Accesswire

Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by ARS Pharmaceuticals, Inc. (SPRY)

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

15 days ago - Accesswire

Levi & Korsinsky Reminds Shareholders of an Investigation into ARS Pharmaceuticals, Inc. (SPRY) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violation...

16 days ago - Accesswire

Shareholder Rights Advocates at Levi & Korsinsky Investigate ARS Pharmaceuticals, Inc. (SPRY) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violations...

20 days ago - Accesswire

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients f...

21 days ago - GlobeNewsWire

Lost Money on ARS Pharmaceuticals, Inc.(SPRY)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violations...

21 days ago - Accesswire

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves...

22 days ago - GlobeNewsWire

ATTENTION SPRY SHAREHOLDERS: Investors who lost money on ARS Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violations...

22 days ago - Accesswire

ARS Being Investigated on Behalf of ARS Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violations...

23 days ago - Accesswire

ARS Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SPRY

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violations...

24 days ago - Accesswire

Levi & Korsinsky Announces an Investigation on Behalf of ARS Pharmaceuticals, Inc. (SPRY) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ:SPRY) concerning possible violat...

4 weeks ago - Accesswire

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients fr...

4 weeks ago - GlobeNewsWire

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients fr...

5 weeks ago - GlobeNewsWire

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter

Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection

5 weeks ago - GlobeNewsWire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients fr...

7 weeks ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceut...

2 months ago - Accesswire